Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-LVH
NCT02956811Phase 4Completed
- Sponsor
- University of Dundee
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and left ventricular hypertrophy (LVH) (2 arms), sponsored by University of Dundee. Primary endpoint: Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks. Started Feb 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT02956811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956811.